Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: A comparison to whole-body magnetic resonance imaging alone

Investigative Radiology

Volumn 49, Issue 12, 2014, Pages 808-815

  Grueneisen, Johannes ^a   Beiderwellen, Karsten ^a   Heusch, Philipp ^b   Gratz, Marcel ^a,c   Schulze Hagen, Antonia ^a   Heubner, Martin ^a   Kinner, Sonja ^a   Forsting, Michael ^a   Lauenstein, Thomas ^a   Ruhlmann, Verena ^a   Umutlu, Lale ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c ERWIN L HAHN INSTITUTE FOR MAGNETIC RESONANCE IMAGING   (Germany)

Author keywords

Fluorine 18 fluorodeoxyglucose; MRI; Pelvic malignancies; PET MRI; Tumor recurrences; Whole body staging

Indexed keywords

FLUORODEOXYGLUCOSE; GADOBUTROL; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GRANULOMA; HISTOPATHOLOGY; HUMAN; IMAGE RECONSTRUCTION; INTERMETHOD COMPARISON; LUNG LESION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PELVIS CANCER; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; UTERINE CERVIX CANCER; WHOLE BODY MRI; WHOLE BODY PET; COMPARATIVE STUDY; DIAGNOSTIC USE; GENITAL NEOPLASMS, FEMALE; IMAGE ENHANCEMENT; IMAGE PROCESSING; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; WHOLE BODY IMAGING; YOUNG ADULT;

ADULT; AGED; CERVIX UTERI; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; OVARIAN NEOPLASMS; OVARY; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; UTERINE CERVICAL NEOPLASMS; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84925970279     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000086     Document Type: Article

References (37)

1. Liyanage SH, Roberts CA, Rockall AG. MRI and PET scans for primary staging and detection of cervical cancer recurrence. Womens Health (Lond Engl). 2010;6:251-267.
2. Hauth EA, Antoch G, Stattaus J, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol. 2005;56:263-268.
3. Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71:164-174.
4. Tsuboyama T, Tatsumi M, Onishi H, et al. Assessment of combination of contrastenhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses. Invest Radiol. 2014;49:524-531.
5. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1209.
6. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
7. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35:1439-1448.
8. Mittra E, El-Maghraby T, Rodriguez CA, et al. Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1952-1959.
9. Chen YM, Chen T, Zee CS, et al. Is there an impact of 18F-FDG PET/CTon the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center. Nucl Med Commun. 2014;35:347-352.
10. Takekuma M, Maeda M, Ozawa T, et al. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol. 2005;10:177-181.
11. Sironi S, Buda A, Picchio M, et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology. 2006;238:272-279.
12. Bipat S, Glas AS, van der Velden J, et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol. 2003;91:59-66.
13. Nakajo K, Tatsumi M, Inoue A, et al. Diagnostic performance of fluorodeoxyglucose positron emission tomography/magnetic resonance imaging fusion images of gynecological malignant tumors: comparison with positron emission tomography/computed tomography. Jpn J Radiol. 2010;28:95-100.
14. Kim SK, Choi HJ, Park SY, et al. Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer. 2009;45:2103-2109.
15. Schmidt H, Brendle C, Schraml C, et al. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Invest Radiol. 2013;48:247-255.
16. Schmidt H, Schwenzer NF, Bezrukov I, et al. On the quantification accuracy, homogeneity, and stability of simultaneous positron emission tomography/magnetic resonance imaging systems. Invest Radiol. 2014;49:373-381.
17. Beiderwellen K, Gomez B, Buchbender C, et al. Depiction and characterization of liver lesions in whole body [(1) (8) F]-FDG PET/MRI. Eur J Radiol. 2013;82:669-675.
18. Wetter A, Lipponer C, Nensa F, et al. Evaluation of the PET component of simultaneous [F]choline PET/MRI in prostate cancer: comparison with [F]choline PET/CT. Eur J Nucl Med Mol Imaging. 2013;41:79-88.
19. Heusch P, Kohler J, Wittsack HJ, et al. Hybrid [(1) (8) F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC). Eur J Radiol. 2013;82:2055-2060.
20. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dualmodality PET/CT in preoperative staging. Radiology. 2003;229:526-533.
21. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:362-372.
22. Beckmann MW, Mallmann P, Uterus Commission of the Gynecological Oncology Wrking Group (AGO). Interdisciplinary S2k guideline on the diagnosis and treatment of cervical carcinoma. J Cancer Res Clin Oncol. 2009;135:1197-1206.
23. German Guideline Programmin Oncology (GGPO) S3-GuidelineonDiagnostics, Therapy and Follow-up of Malignant Ovarian Tumours Long version 1.1-AWMF registration number: 032/035OL, June 2013. Available at: http://www.awmf.org/leitlinien/detail/ll/032-035OL.html. Accessed March 10, 2014.
24. Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, et al. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013;48:273-279.
25. Buchbender C, Hartung-Knemeyer V, Beiderwellen K, et al. Diffusionweighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection? Eur J Radiol. 2013;82:877-882.
26. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
27. Chung HH, Kim SK, Kim TH, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol. 2006;103:165-170.
28. Ryu SY, Kim K, Kim Y, et al. Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease. J Korean Med Sci. 2010;25:1029-1033.
29. Murakami M, Miyamoto T, Iida T, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16(suppl 1):99-107.
30. Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007;105:17-22.
31. Hu YY, Sun XR, Lin XP, et al. Application of 18F-FDG PET/CT in cervical cancer with elevated levels of serum squamous cell carcinoma antigen during the follow-up [in Chinese]. Ai Zheng. 2009;28:994-999.
32. Michielsen K, Vergote I, Op de Beeck K, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014;24:889-901.
33. Makhija S, Howden N, Edwards R, et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53-58.
34. Amit A, Beck D, Lowenstein L, et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol. 2006;100:65-69.
35. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106:29-34.
36. Koolen BB, van der Leij F, Vogel WV, et al. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer. Acta Oncol. 2014;53:50-57.
37. Kitajima K, Suenaga Y, Ueno Y, et al. Value of fusion of PET and MRI in the detection of intra-pelvic recurrence of gynecological tumor: comparison with F-FDG contrast-enhanced PET/CT and pelvic MRI. Ann Nucl Med. 2014;28:25-32.